Ophthalmologic Baseline Characteristics and 2-Year Ophthalmologic Safety Profile of Pramipexole IR Compared with Ropinirole IR in Patients with Early Parkinson’s Disease
Table 5
Subgroup analysis: summary of Expert Panel’s comprehensive ophthalmology assessment (COA) following 2 years on study drug (full analysis set, last observation carried forward [LOCF]). Shown are numbers of patients in each subgroup assessed to have worsening from baseline on the COA, as defined in the legend of Table 4/number of patients in each subgroup within each treatment arm.
Pramipexole
Ropinirole
Number worse from baseline, n (%)
34 (29.6)
33 (27.7)
Gender, (%)
Male
24/74 (32.4)
18/77 (23.4)
Female
10/41 (24.4)
15/42 (35.7)
Race, n (%)
White
32/107 (29.9)
32/115 (27.8)
Nonwhite
2/8 (25.0)
1/4 (25.0)
Age in years, n (%) (age grouping 1)
<65
23/91 (25.3)
25/88 (28.4)
≥65
11/24 (45.8)
8/31 (25.8)
Age in years, n (%) (Age Grouping 2)
<50
4/22 (18.2)
6/17 (35.3)
50 to <65
19/69 (27.5)
19/71 (26.8)
65 to <75
7/19 (36.8)
5/27 (18.5)
≥75
4/5 (80.0)
3/4 (75.0)
Concomitant use of levodopa, n (%)
No
25/82 (30.5)
16/68 (23.5)
Yes
9/33 (27.3)
17/51 (33.3)
Hoehn–Yahr stage at baseline, n (%)
1
9/26 (34.6)
8/23 (34.8)
1.5
3/10 (30.0)
2/17 (11.8)
2
19/69 (27.5)
21/69 (30.4)
2.5
2/7 (28.6)
1/5 (20.0)
3
1/3 (33.3)
1/5 (20.0)
Eight subjects were assessed as “worse from baseline” based on responses carried forward (2 subjects in the pramipexole group and 6 in the ropinirole group).
